

**CIRCULAR TO SHAREHOLDERS**

**CSIF (IE) MSCI USA Blue UCITS ETF (the "Fund")**

**a sub-fund of**

**Credit Suisse Index Fund (IE) ETF ICAV (the "ICAV")**

an umbrella fund with segregated liability between sub-funds

**NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING TO BE HELD VIA ELECTRONIC COMMUNICATIONS TECHNOLOGY, NAMELY MICROSOFT TEAMS, AT 10A.M. IRISH TIME, ON 16 AUGUST 2024 AT 3<sup>RD</sup> FLOOR, 55 CHARLEMONT PLACE, DUBLIN, D02 F985, IRELAND, IS SET OUT IN SCHEDULE 4.**

**This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should consult your stockbroker, investment advisor or consultant, bank manager, solicitor, accountant or other professional adviser.**

**If you have sold or transferred all of your Shares, you should pass this document, together with the relevant accompanying documents, to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was made for transmission to the purchaser or transferee as soon as possible.**

**A Notice convening an Extraordinary General Meeting (the "EGM") of Shareholders of the Fund is enclosed at Schedule 4. Please complete the enclosed form of proxy and return by email to [carnecosec@carnegroup.com](mailto:carnecosec@carnegroup.com) with original to follow by post for the attention of the Secretary, Credit Suisse Index Fund (IE) ETF ICAV, 3<sup>rd</sup> Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland. All proxy votes in whichever format provided must arrive no later than two full business days in Ireland before the time of the meeting. The meeting will take place at 10.00 a.m. (Irish time) on 16 August 2024.**

**Capitalised terms used in this document shall bear the same meaning as the defined terms used in the prospectus of the ICAV dated 01 December 2022 (the "Prospectus") including the supplement of the Fund dated 01 December 2022 (the "Supplement"). A copy of the Prospectus and the Supplement are available upon request during normal business hours from the registered office of the ICAV or from such other persons specified by the ICAV.**

**Dated 19 July 2024**

**Credit Suisse Index Fund (IE) ETF ICAV**  
**3rd Floor, 55 Charlemont Place**  
**Dublin, D02 F985**  
**Ireland**

Date: 19 July 2024

Dear Shareholder,

We are writing to you as a Shareholder of the CSIF (IE) MSCI USA Blue UCITS ETF, a sub-fund of Credit Suisse Index Fund (IE) ETF ICAV.

The purpose of this shareholder circular ("**Circular**") is to explain to you the proposal to merge the Fund with UBS (Irl) ETF plc – MSCI USA NSL UCITS ETF, a newly established sub-fund of UBS (Irl) ETFs Plc and to give you notice of a general meeting of the Shareholders of the Fund at which the merger proposal can be considered.

***Details of the proposed merger of the Fund into a sub-fund of UBS (Irl) ETFs Plc (the "Receiving Platform") namely, UBS (Irl) ETF plc – MSCI USA NSL UCITS ETF (the "Receiving Fund") (the "Merger").***

The proposal is to merge the Fund with the Receiving Fund pursuant to Clause 42 of the Instrument of Incorporation of the ICAV (the "**Instrument**") and in accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulation 2011 (S.I. No. 352 of 2011), as amended (the "**Regulations**") and to seek your approval for the proposal.

This Circular has been reviewed and cleared in advance by the Central Bank of Ireland (the "**Central Bank**") pursuant to Regulation 57 of the Regulations.

It is proposed that the Merger take place in accordance with Regulation 3(1) of the Regulations, meaning that, once the Merger is approved, on the day the Merger takes effect, all of the assets and liabilities of the Fund will transfer to the Receiving Fund and the Shareholders of the Fund will become shareholders of the Receiving Fund. They will therefore, as at the Effective Time, receive Shares in the corresponding share class of the Receiving Fund (the "**New Shares**"), as further detailed in the section below entitled "*Details of Subscriptions in the Receiving Fund*". The Fund will then be dissolved without going into liquidation.

Details of the relevant classes of New Shares which you will receive as a result of the Merger are set out in Schedule 1 to this document and the Key Information Documents ("**PRIIPs KID**"), and to the extent applicable, the Key Investor Information Document ("**KIID**"), for the Receiving Fund, which has been noted by the Central Bank, are set out in Schedule 3 to this document.

***Background of the Fund and the Receiving Fund***

The investment objective and policy of the Fund and the Receiving Fund are broadly similar. Both the Fund and the Receiving Fund aim to provide Shareholders with a return in line with the performance of the MSCI USA ESG Leaders Index (Net Return). The key differences between the Fund and the Receiving Fund are specifically highlighted in Schedule 1 and include (a) the change from the ICSD Model to the ICSD+ Model; (b) a change in ISINs; (c) a reduction in the total expense ratio and removal of any entry/exit fees; (d) a change in the financial reporting period (for the ICAV in respect of this financial period and a change for investors merging into the Receiving Fund); (e) additional financial derivative instruments which may be used for efficient portfolio management purposes; (f) increase in tracking error and (g) removal of any minimum thresholds for investment.

There are no material differences between the key risks associated with the Fund and the Receiving Fund. There is no assurance that the Receiving Fund will achieve its investment objective. The Receiving Fund is not guaranteed and Shareholders may lose some or all of the amounts they have invested in the Receiving Fund.

The Receiving Fund was approved by the Central Bank as a sub-fund of the Receiving Platform on 10 June 2024 and has yet to be seeded. As such, the Fund's Shareholders will constitute the first shareholders in the Receiving Fund.

The Receiving Fund is formally registered for sale to the public in each of the Member States of the European Union in which the Fund is currently so registered and is currently listed on all of the same Relevant Stock Exchanges as the Fund is listed on.

### ***Effective Date/ Time of Merger***

Subject to the approval of the Merger at the EGM, the Merger will become effective as at 00:00:01 a.m. Irish time on 26 August 2024 (the "**Effective Date**").

### ***Rationale for the Merger***

In March 2023, UBS Group AG agreed to buy Credit Suisse, and on 7 December 2023 it was announced that the directors of UBS Group AG had approved the execution of a merger of UBS AG and Credit Suisse AG. As part of that broader merger project, it is proposed to consolidate the Irish platforms of those two entities such that the existing sub-funds of the ICAV would merge onto the Receiving Platform.

Given the Receiving Platform is significantly bigger than the ICAV, investors in the Fund will benefit from economies of scale achieved through the merger. Additionally, UBS AG has a significantly larger distribution network than Credit Suisse, which will provide greater opportunities for the Fund to increase assets and attract new investors and will ultimately improve the potential opportunities for better performance for investors.

### ***Timing/ EGM Procedure***

Shareholders are required to approve the Merger by way of special resolution before it may proceed. Such resolution may be passed at an extraordinary general meeting of the ICAV (an "**EGM**"). At the EGM, Shareholders will be asked to consider as an item of business the approval of the Merger. In order for the Merger to be effective, the special resolution to be considered at the EGM of the Fund requires three quarters of those present and voting in person or by proxy to vote in favour of the resolution. You will find attached a notice of EGM in respect of the Fund.

In order to consider the proposals set out in this document, you are advised firstly to read all of the enclosed documentation. If you have any questions, you should contact <https://am.credit-suisse.com/contact> or your own professional advisor. Please then register your vote in person at the EGM by completing and returning the enclosed form of proxy in accordance with the notes set out on the relevant form. To be valid, forms of proxy must be received by the secretary of the ICAV not later than 48 hours before the time fixed for holding the EGM.

One person entitled to vote upon the business to be transacted, being a Shareholder or a duly authorised representative of a Shareholder (each, a "**Holder**") or a proxy for such Holders, shall be a quorum at the EGM.

If a quorum is not present for the EGM within half an hour from the time appointed, the EGM will automatically be adjourned to the same time on the same day of the following week and will be convened at the same address. At the adjourned EGM, any number of Shareholders of the Fund (including just one) present or represented in person or by proxy will constitute a quorum.

If the resolution relating to the Merger is passed by the Shareholders of the Fund at the EGM, or any adjournment thereof, it is expected that the Merger will take effect on the Effective Time.

You will be notified, by letter, of the outcome of this EGM and, if the Merger is approved, the last dealing day in Shares of the Fund will be at the final Dealing Day prior to the Effective Time. Furthermore, the outcome of the EGM (or of any adjournment thereof) will be notified to Shareholders by way of release of an announcement that will be posted on <https://am.credit-suisse.com/notice-to-investors>.

Thereafter you will be advised in writing by the Receiving Fund's administrator within five business days following the Effective Time of the number of New Shares issued to you in the Receiving Fund. Subject to the Dealing Deadline provisions set out in the supplement of the Receiving Fund, you may deal in New Shares of the Receiving Fund on the next business day after the Effective Time.

The Form of Proxy accompanying the notice of the EGM enclosed with this Circular is for use in relation to the EGM and should be completed and returned in accordance with the instructions thereon, and to be received as soon as possible and in any event not later than 10.00 a.m. (Irish time) on 14 August 2024, being two business days before the time fixed for the holding of the EGM. Shareholders may return a

signed copy of the Form of Proxy by email to [carnecosec@carnegroup.com](mailto:carnecosec@carnegroup.com), with the original to follow by post to 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland, for the attention of the Secretary of Credit Suisse Index Fund (IE) ETF ICAV. Completion and return of a Form of Proxy will not preclude you from attending and voting in person at the EGM.

It should be noted that, if the resolution is approved by the requisite majority, the Merger will be binding on all Shareholders, including Shareholders who voted against it or who did not vote at all. However, as noted above, if the Merger is approved, you will have the opportunity until the Redemption Deadline to redeem your existing Shares before the Merger takes effect free of any redemption charge, subject to the procedures set out in the Prospectus.

### ***Expected impact of Merger***

The Merger ultimately will result in the following:

- (a) all the assets and liabilities of the Fund being transferred to the Receiving Fund;
- (a) the Shareholders of the Fund becoming Shareholders of the Receiving Fund; and
- (b) the Fund being dissolved without going into liquidation.

Schedule 1 sets out a comparison of the key features and operation of the Fund and the Receiving Fund. For the avoidance of doubt, and as noted within the above section entitled "*Background of the Fund and the Receiving Fund*", there are no material differences between the Fund and the Receiving Fund, save for those which will be considered by the Shareholders and approved by them by way of special resolution at the EGM.

The Receiving Fund will value its investments and issue and redeem shares on a daily basis, thereby offering the same liquidity as the Fund.

#### a) Change from ICSD to ICSD+ Model

The settlement of trading in Shares of the Fund is centralised in an ICSD structure. Shares in the Fund are issued in dematerialised form and no temporary documents of title or share certificates will be issued, other than the Global Share Certificate issued to the Bank of New York (Depository) Nominees Limited as the Common Depository's Nominee which is required for the ICSD settlement model. The Fund applies for admission for clearing and settlement through the applicable ICSD. The ICSD for the Fund is Euroclear and Clearstream, Luxembourg.

The Receiving Platform operates an ICSD+ model, which provides centralised issuance of shares in Clearstream, and allows for the centralised settlement in the ICSD structure jointly operated by Clearstream and Euroclear. Under the ICSD+ model, Clearstream effectively operates the role of the common depository, as the participants open a Fund Issuance Account (FIA) within Clearstream. This obviates the need for the creation of a Global Share Certificate.

The change from ICSD to ICSD+ model should not result in any significant difference in the manner in which shares are settled post-merger.

#### b) Change in ISIN

Given that it is proposed that the Merger will proceed by way of merger by absorption, it is required that new ISINs are issued in respect of each of the Share Classes. Details of the ISINs of the existing Share Classes and the corresponding ISINs of the new share classes are set out in the Share Class Transfer Table in Schedule 1 hereto.

#### c) Reduction in TER and change in fees

As set out in the Share Class Transfer Table in Schedule 1, the maximum TER chargeable for the Unhedged Share Classes in the Fund is up to 0.15% per annum, and in respect of the Hedged Share Classes the maximum TER is up to 0.18%. Shareholders should note that pursuant to the terms of the Receiving Fund supplement, the maximum TER in respect of unhedged share classes is up to 0.09% per annum and the maximum TER in respect of the hedged share classes is up to 0.12% per annum.

Additionally, the Fund has the ability to levy a Subscription Charge (up to 5%), Repurchase Charge (up to 3%), Exchange Charge (up to 3%) and Primary Market Transaction Charge (up to 1%). All

of the fees relating to the Receiving Fund are paid through the flat fee/TER of the Receiving Fund, and there is no ability for the Receiving Fund to levy entry or exit charges in the same manner as the Fund. Shareholders should note that, to-date, no entry/exit charges have been levied by the Fund.

d) Change in Financial Reporting Period

Pursuant to the terms of the Prospectus, the Accounting Period of the ICAV is the period ending 31 March of each year. In contemplation of the Merger and the subsequent winding up of the ICAV, the ICAV has sought, and the Central Bank has granted, a derogation in order to extend the Accounting Period to 30 September 2024. Accounts shall be prepared for the period from 1 April 2023 until 30 September 2024, and it is intended that following the preparation of such accounts, that an application for the revocation of the ICAV's approval as a regulated collective investment scheme will be submitted to the Central Bank.

Shareholders should also note that the accounting period for the Receiving Platform ends on 31 December in each year.

e) Use of FDI

In order to achieve its investment objective, the Fund may engage in transactions in warrants, FX forwards and futures for the purposes of efficient portfolio management and/or to protect against exchange risks within the conditions and limits laid down by the Central Bank from time to time. In addition to the financial derivative instruments listed above, the Receiving Fund may also use futures on stocks; currency swaps and currency forwards for efficient portfolio management purposes and/or currency hedging purposes.

f) Tracking Error

The Fund anticipates that in normal market conditions, the level of tracking error will be less than 0.60%. In respect of the Receiving Fund, its investment manager or sub-investment manager aims to keep the tracking error below or equal to 1% in normal market conditions.

g) Minimum thresholds

The Fund has certain minimum thresholds in relation to Minimum Initial Investment Amount (25,000 shares), Minimum Additional Investment Amount (25,000 shares), Minimum Repurchase Amount (25,000 shares) and Minimum Shareholding (25,000 shares). In each case, these minimum thresholds are subject to the discretion of the directors of the ICAV (or their delegate) to waive such minimum amounts.

The Receiving Fund does not have any minimum holding, minimum subscription amount or minimum redemption amount.

Furthermore, any legal, advisory or administrative costs associated with the preparation and completion of the Merger will not be charged to either the Fund or the Receiving Fund, nor any of their Shareholders. These costs will be borne by UBS Asset Management Switzerland AG, as addressed in more detail below under the heading "*Costs of the Merger*".

All documentation you provided to the ICAV in relation to your subscription for shares in the Fund (i.e. the original signatory lists/ powers of attorney, if applicable, bank details and original anti-money laundering verification documentation) will be deemed to apply to your holding in the Receiving Fund post the Merger having taken effect. In addition, the representations and warranties which you provided as part of your application for shares in the Fund are deemed to be repeated in respect of your holding in the Receiving Fund.

It is not expected that there will be any realignment of the portfolio of assets of the Fund in anticipation of implementing the Merger. Where it is efficient to do so, securities held by the Fund will transfer *in specie* to the Receiving Fund on the Effective Date. However, in certain emerging markets it is more efficient to effect this transaction by way of a sale and repurchase of securities, rather than by way of a transfer of those securities. In such circumstances, securities of the Fund's portfolio, will be sold at or shortly before the Effective Date and a matching order for the purchase of those securities will be made by the Receiving Fund at that time. As far as possible, the number and traded prices of the securities to be sold by the Fund for this purpose will match the number and traded prices of the securities to be purchased by the Receiving

Fund. Accordingly, it is not anticipated that shareholders will be "out of the market" as a result of the Merger to any material extent.

### ***Temporary Suspension***

If the resolution to be tabled at the EGM is passed by Shareholders, the Directors intend to temporarily suspend all dealing in the shares of the Fund on both primary and secondary markets to facilitate the implementation of the Merger. This suspension will commence on 21 August 2024 and carry through until 23 August 2024 inclusive.

Shareholders in the Fund who have requested the redemption of shares in the Fund during this suspension period will have their requests returned and will be requested to re-direct their redemption request to the Receiving Fund. Similarly, applications for the issue of shares in the Fund during this suspension period will be returned and such applicants will be requested to consider subscribing for shares in the Receiving Fund.

### ***Change of Financial Year End***

Should Shareholders approve the Merger, Shareholders are advised that it is intended following the Merger to wind-up the ICAV and to seek the revocation of its authorisation from the Central Bank. In that respect, the ICAV has applied for, and the Central Bank has granted to the ICAV, a derogation from preparing audited financial statements for the period ending 31 March 2024 on the basis that a set of termination financial statements will be prepared for the period from 1 April 2023 until 30 September 2024. As such, Shareholders in the Fund as at 31 March 2024 shall be entitled to receive the financial statements for the period ending 30 September 2024, once these have been finalised.

### ***Details of Subscriptions in the Receiving Fund***

You are advised that, if the Merger is approved, you will receive New Shares in the corresponding class in the Receiving Fund. Shares in the Receiving Fund will be issued at the Net Asset Value per Share of the relevant Class as calculated as at the Valuation Point of the Fund. Brown Brothers Harriman Fund Administration Services (Ireland) Limited (the "**Administrator**"), will calculate the net assets being transferred as part of the Merger pursuant to the Instrument and the Prospectus. The number of New Shares to be issued in the relevant class of the Receiving Fund shall be the number which would, on the Effective Time, have been issued for cash against the payment of a sum equal to the value of the net assets being transferred from the Fund. For the avoidance of doubt, your existing Shares in the Fund will be cancelled when the New Shares are issued on the Effective Time.

The valuation of the net assets shall be verified by PwC, the auditors of the Fund (the "**Auditor**") to ensure consistency with the Instrument, the Prospectus and the requirements of the Regulations.

Provided that you have not redeemed your existing Shares in the Fund, the Receiving Fund administrator will issue you with a written confirmation of ownership of New Shares in the Receiving Fund within five business days of the Effective Time. Subject to the Subscription Dealing Deadline provisions set out in the supplement for the Receiving Fund, you may deal in the New Shares of the Receiving Fund on the next business day after the Effective Time. For the avoidance of doubt, the existing Shares in the Fund will be cancelled when the New Shares are issued as at the Effective Time.

No initial charge will be made on the issue of New Shares in the Receiving Fund as part of this process.

Please see the Share Class Transfer table in Schedule 1 for more details in respect of the New Shares.

### ***Redemption of Shares***

If the Merger is approved, Shareholders will have until the Redemption Deadline to redeem existing Shares before the Merger takes effect, free of any redemption charge, subject to the procedures set out in the Prospectus.

If a person asks to receive a copy of the Fund documents or seeks to subscribe for new shares in the Fund between the date of this Circular and the Effective Time, such person will be provided with the PRIIPs KID or KIID for the Fund and will also be provided with a copy of this Circular and the PRIIPs KID or KIID for the Receiving Fund.

### ***Costs of the Merger***

Save for any costs related to unamortised establishment costs of the Fund, all costs in connection with the Merger and the transfer of net assets to the Receiving Fund (including the costs of calling the meeting of Shareholders and of the preparation and implementation of the transfer) will be borne by UBS Asset Management Switzerland AG.

Following the Effective Time, the Shareholders in their capacity as shareholders of the Receiving Fund will be subject to the costs of operation of the Receiving Fund.

### **Tax**

The tax consequences of implementation of the Merger may vary depending on the law and regulations of your country of residence, citizenship or domicile and it is possible that your tax treatment will change following the Merger. If you are in any doubt about your potential liability to tax, you should seek professional advice.

### **Enclosures/ Documents available for display**

As mentioned above, the PRIIPS KID and KIIDs of the Receiving Fund, which contains key investor information relating to the Receiving Fund, is enclosed. The Directors recommend that you review these documents as well as the Prospectus of the Receiving Platform and the supplement for the Receiving Fund in order to familiarise yourself with the key investor information in respect of the Receiving Fund. Copies of the memorandum and articles of association of the Receiving Platform, latest annual and semi-annual reports, material contracts, Prospectus of the Receiving Platform, the supplement of the Receiving Fund and a copy of the report of the Auditor (once available) are available free of charge and may be inspected at the registered office of the Receiving Platform.

### **Regulatory Considerations**

The Central Bank has reviewed the contents of this circular in accordance with the requirements of the Regulations.

Please note that Brown Brothers Harriman Trustee Services (Ireland) Limited, the depositary of the Fund (the "**Depositary**") is satisfied with the Merger proposal and has confirmed to the Central Bank that it has no objection to the proposal being put before you for approval.


In accordance with the requirements of Regulation 59 of the Regulations, each of (i) the Depositary and (ii) the Receiving Platform's depositary will provide written verification of the type of merger and the UCITS involved, the Effective Date and that the rules applicable, respectively, to the transfer of the assets and liabilities of the Fund and the exchange of shares are in accordance with the Regulations and the relevant constitutional documents.

If you would like any further information about the Merger, please contact your usual contact at the ICAV.

### **Recommendation**

The Directors, based on the recommendation and information received from Credit Suisse and UBS, believe that the Merger is aligned with the interests of the Shareholders in the Fund as a whole and, accordingly, the Directors recommend that you vote in favour of the Merger at the EGM.

Yours sincerely,

DocuSigned by:  
  
E6DFD2982E54458...

Director

For and on behalf of

Credit Suisse Index Fund (IE) ETF ICAV

*Schedule 1: Differences between the Fund and the Receiving Fund & Details of Share Classes in the Receiving Fund.*

*Schedule 2: Timeline for proposals*

*Schedule 3: PRIIPs KID and KIIDs for the Receiving Fund.*

*Schedule 4: Notice of an Extraordinary General Meeting of the Fund.*

*Schedule 5: Form of proxy for Extraordinary General Meeting of the Fund.*





**Schedule 1**  
**Differences between the Fund and the Receiving Fund**  
**&**  
**Details of Share Classes in the Receiving Fund**

	<b>Fund</b>	<b>Receiving Fund</b>
<b>Name of ICAV</b>	Credit Suisse Index Fund (IE) ETF ICAV	UBS (Irl) ETF Plc
<b>Name of Sub-Fund</b>	CSIF (IE) MSCI USA Blue UCITS ETF	UBS (Irl) ETF Plc – MSCI USA NSL UCITS ETF
<b>Regulatory status and structure</b>	Authorised in Ireland as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011	No difference
<b>Manager</b>	Carne Global Fund Managers (Ireland) Limited	UBS Fund Management (Ireland) Limited
<b>Investment Manager</b>	Credit Suisse Asset Management (Switzerland) Ltd.	UBS Asset Management (UK) Ltd
<b>Depository</b>	Brown Brothers Harriman Trustee Services (Ireland) Limited	State Street Custodial Services (Ireland) Limited
<b>Administrator</b>	Brown Brothers Harriman Fund Administration Services (Ireland) Limited	State Street Fund Services (Ireland) Limited

<p><b>Investment objective and policy (capitalized terms used but not defined shall have the meanings ascribed to them in the relevant Supplement)</b></p>	<p><b>Investment Objective</b></p> <p>The Fund tracks the MSCI USA Index as its benchmark index. The investment objective of the ETF is to provide the Shareholders with a return in line with the performance of the MSCI USA Index (the "<b>Reference Index</b>"), less the fees and expenses of the Fund.</p> <p><b>Investment Policies</b></p> <p>In order to achieve the investment objective, the Fund intends to invest all or substantially all of the net proceeds of any issue of Shares in the following:</p> <p>(i) Equities and Equity-Related Securities which relate to the components of the Reference Index, in order to replicate as closely as possible the performance of the Reference Index. Consequently, the prime criterion for selecting the individual Equities and Equity-Related Securities is not their perceived attractiveness or potential growth or value but rather their suitability in terms of attaining the investment objective of replicating the performance of the Reference Index. The Fund may invest up to 20% of its Net Asset Value in such Equities and Equity-Related Securities issued by the same body in order to replicate the Reference Index. The limit may be raised to 35% for a single issuer where exceptional market conditions apply.</p>	<p><b>Investment Objective</b></p> <p>The objective of the Fund is to seek to track the equity market performance of the US market.</p> <p><b>Investment Policy</b></p> <p>The investment policy of the Fund is to seek to track the performance of the MSCI USA Index (Net Return) (or any other index determined by the Directors from time to time to track substantially the same market as the MSCI USA Index (Net Return) and which is considered by the Directors to be an appropriate index for the Fund to track), in accordance with the Prospectus (the "<b>Index</b>") as closely as possible, while seeking to minimise as far as possible the difference in performance between the Fund and the Index. Any determination by the Directors that the Fund should track another index at any time shall be subject to the provision of reasonable notice to Shareholders and implemented in accordance with the requirements of the Central Bank and this Supplement shall be updated accordingly. The Fund will use replication techniques as described below in order to minimise as far as possible the difference in performance between the returns of the Index and the return of the Fund, after Fees and Expenses. For information in relation to the difficulties associated with tracking indices, please refer to "<i>Index Tracking Risk</i>" in the "<i>Risk Information</i>" section of the Prospectus.</p> <p>The Fund is passively managed.</p> <p>The Fund complies with Article 6 of SFDR. As such it does not consider principal adverse impacts on sustainability factors due to its investment strategy and the nature of the underlying investments (SFDR Art. 7(2)). The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities (TR Art. 7).</p> <p>In order to seek to achieve this investment objective, the Investment Manager, on behalf of the Fund, will invest, using the Replication Strategy, primarily in the securities of the Index in the approximate weightings of the Index subject to the Investment Restrictions set forth in the Prospectus. These securities (which may include depositary receipts) shall be listed and/or traded on the exchanges and markets set out in Schedule II of the Prospectus. This strategy seeks to hold all of the securities of the Index, with the approximate weightings as in that Index, so that essentially, the portfolio of the Fund will be a near mirror-image of the components of the Index. There are also currency versions of the Index which are denominated in a currency other than US Dollars and hedged, including currency versions denominated in EUR and CHF (each a "<b>Hedged Currency Version</b>"), as detailed in the table below. The purpose of the Hedged Currency Versions is to limit the profit or loss generated from foreign exchange exposure when holding an US Dollar denominated asset in a currency other than US Dollars. This is achieved by the Hedged Currency Versions employing one month rolling forward FX contracts. In accordance with the Hedged Currency Versions methodologies the Fund may also employ rolling</p>
--	---	---

(ii) temporarily in Equities and Equity-Related Securities and rights of companies which are not contained in the benchmark index but where there is a high probability that such securities will be able to join the MSCI USA Index on the basis of its acceptance criteria. In order to keep aligned with the investment objective of the Fund (i.e to deliver a return in line with the performance of the Reference Index), the expected maximum of such temporary investment is 5% of Net Asset Value.

(iii) in units of passively managed collective investment schemes, both domestic and foreign and listed and unlisted, that are consistent with the investment objective and meet with the requirements of the UCITS Regulations.

(iv) Investments (including derivatives on these investments) which are dropped from the Reference Index must be sold within an appropriate period (usually within 10 business days) while safeguarding the interests of the investors.

The Equities, Equity-Related Securities, other eligible assets listed above, any ancillary cash and any instruments (held for the purposes of efficient portfolio management and currency hedging) held by the Fund shall constitute the "Fund Assets" for the purposes of the Prospectus.

forward FX contracts to limit the profit or loss generated from foreign exchange exposure when holding an US Dollar denominated asset in a currency other than US Dollars. Shareholders should note that the disclosure in respect of the Hedged Currency Versions is for information purposes only and is to explain the manner in which the Fund will engage in currency hedging. Further details regarding the Replication Strategy are disclosed in the "*Investment Objectives, Policy and Strategy*" section of the Prospectus.

Share Class	Index Currency Version
(hedged to EUR) A-acc; (hedged to EUR) A-dis;	MSCI USA 100% hedged to EUR Index (Net Return)
(hedged to CHF) A-dis; (hedged to CHF) A-acc;	MSCI USA 100% hedged to CHF Index (Net Return)

In seeking to implement its investment objective of tracking the performance of the Index, the Fund may in exceptional circumstances also hold securities which are not comprised in its Index, including, for example, securities in respect of which there has been an announcement or it is expected that they will shortly be included in the Index or where there are considerable costs or difficulties associated with purchasing the Index constituent and the Investment Manager identifies securities whose risk and return characteristics closely resemble the risk and return characteristics of constituents of the Index or of the Index as a whole. In such case, the relevant securities shall not have received an ESG rating from the Index Provider. Solely for the purposes of assisting in replicating the Index. The Fund may also invest in securities which are not constituents of the Index where the Investment Manager considers that such securities may provide a similar return to certain securities that make up the Index. The Fund may avail of the higher investment limits allowed to certain index tracking funds, as described at paragraph 4.2 of the section of the Prospectus headed "Investment Restrictions". These limits may be availed of where exceptional market conditions apply for example if there is an increased allocation of an issuer within the Index. These exceptional market conditions include where a single constituent may, for various reasons, including as a result of a merger, have a very dominant position. If the investment limits of the Fund are exceeded for reasons beyond the control of the Directors, or as a result of the exercise of subscription rights, the Fund must adopt as a priority objective for its sales transactions the remedying of that situation, taking due account of the interests of the Shareholders. The Fund as set above utilises the Replication Strategy accordingly, investment in the Fund should be considered to provide a direct exposure to the Index. Details of the Fund's tracking error and trading difference is set out in the section of the Prospectus entitled "*Tracking Accuracy*". For the avoidance of doubt, where the Fund does not use a full Replication Strategy, it will not be permitted to avail of the higher investment limits as described at paragraph 4.2 of the section of the Prospectus headed "Investment Restrictions".

	<p>Irrespective of the investment policy pursued, the Fund will be managed so that it is not leveraged for investment purposes (i.e. a 1:1 exposure). In this regard, any use of derivatives will not result in incremental exposure at the level of the Fund.</p> <p>The investments underlying this Fund do not take into account the EU criteria for environmentally sustainable economic activities.</p> <p>Further information relevant to the Fund's investment policy is contained in the main part of the Prospectus under "Investment Objectives and Policies" and under "Investment Restrictions".</p> <p>Investment Strategy</p> <p>In order to seek to achieve this investment objective, the Investment Manager, on behalf of the Fund, will invest primarily in the securities of the Index in the approximate weightings of the Index subject to the Investment Restrictions set forth in the Prospectus. These securities (which may include depositary receipts) shall be listed and/or traded on the exchanges and markets set out in Appendix II of the Prospectus. This strategy seeks to hold all of the securities of the Index, with the approximate weightings as in that Index, so that essentially, the portfolio of the Fund will be a near mirror image of the components of the Index.</p>	<p>As the Fund does not pursue a synthetic index replication strategy, there is no corresponding counterparty risk applicable. As a result of currency hedging, hedged Share Classes may be exposed to counterparty risk as further detailed in the section of the Prospectus entitled "Counterparty Risk".</p> <p>The Fund (as well as the Index) will take long positions only and the Fund will invest 100% of its net assets in long positions.</p> <p>The Fund may, for the purpose of efficient portfolio management, where disclosed in the Manager's RMP Statement (if applicable) and in accordance with the conditions and limits imposed by the Central Bank, use financial derivative instruments ("<b>FDI</b>") including currency forwards, currency swaps, warrants, index futures and futures on stocks. Efficient portfolio management means investment decisions involving transactions that are entered into for one or more of the following specific aims: the reduction of risk; the reduction of cost; or the generation of additional capital or income for the Fund with an appropriate level of risk, taking into account the risk profile of the Fund and the risk diversification rules set out in the Central Bank Rules. In particular, FDI may be used for the purpose of minimising differences in performance between the Fund and the relevant Index, ie, the risk that the Fund return varies from the Index's return.</p> <p>To the extent that the Investment Manager, on behalf of the Fund, uses FDI, there may be a risk that the volatility of the Fund may increase. It is anticipated that the volatility level of the Fund will be closely correlated with the volatility of the Index. Investors should note that there can be no assurance that the historical volatility levels of the Index will continue to be observed in the future or that the Fund will have a similar volatility level and that, therefore, there is a risk that the Fund's volatility may be relatively high when compared to other investments and may change significantly over time and, as a result, an investment in the Fund may not be appropriate for all investors. That notwithstanding, the Fund is not expected to have an above average risk profile as a result of its use of or investment in FDI. FDI will be used within the limits stipulated by the Central Bank and as described in the "<i>Use of Financial Derivative Instruments</i>" section of the Prospectus. Accordingly, although FDI will be inherently leveraged, the primary purpose of the use of FDI is to minimise as far as possible the difference in performance between the Fund and the Index and, while the Fund will be leveraged as a result of its investments in FDI, such leverage will not exceed 100% of the Fund's total Net Asset Value at any time.</p> <p>The Fund, subject to the restrictions imposed on the use of FDI described in the Prospectus and by the UCITS Regulations, may buy and sell futures contracts to either create exposure or reduce exposure to various securities included in the Index or to reduce certain aspects of risk inherent in specific trades. Futures contracts are agreements to buy or sell a fixed amount of an equity, bond or</p>
--	---	--

	As the Fund does not pursue a synthetic index replication strategy, there is no corresponding counterparty risk applicable.	<p>currency at a fixed date in the future. Futures contracts are exchange-traded instruments and their dealing is subject to the rules of the exchanges on which they are dealt.</p> <p>The Manager has adopted a statement of its risk management processes ("<b>RMP</b>") in respect of the use of FDI which enables it to accurately measure, monitor and manage the various risks associated with FDI and the Fund will employ only FDIs which are described in the RMP. The Manager will only adopt an RMP which has been provided to the Central Bank.</p>
<b>Leverage Limits</b>	100% of the fund's net asset value calculated using the commitment approach	No difference
<b>Valuation Point</b>	means 10.30 p.m. (Dublin time) on the Business Day following the relevant Dealing Day	10.30 pm (Dublin time) on each Business Day.
<b>Dividend Policy</b>	<p>The Sub-Fund does not declare dividends in respect of the Class B USD Shares, the Class BH EUR Shares or the Class BH CHF Shares.</p> <p>Dividends may be declared from the net investment income attributable to the Class A USD Shares, the Class AH EUR Shares and the Class AH CHF Shares. Dividends may be declared annually or at any intervals to be specified by the Board of Directors.</p>	<p>It is not the intention of the sub-fund to declare dividends from the class (USD) A-acc, class (hedged to EUR) A-acc or class (hedged to CHF) A-acc shares.</p> <p>The directors intend to declare dividends semi-annually out of net income and/or realised and unrealised gains net of realised and unrealised losses attributable to the class (USD) A-dis, class (hedged to EUR) A-dis and class (hedged to CHF) A-dis shares.</p>

<p><b>Key risks</b></p>	<p>The Funds are segregated as a matter of Irish law and as such, in Ireland, the assets of one Fund will not be available to satisfy the liabilities of another Fund. However, it should be noted that the ICAV is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There can be no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability as set out above.</p> <p>Upon the occurrence of a Disruption Event or an Index Disruption and Adjustment Event (and without limitation to the Directors' personal powers as further described in the Prospectus); (i) adjustments may be made to account for any such event (including adjustment to the Reference Index, the calculation of the Reference Index level and/or changes to the terms of the derivative contracts) which may have a significant impact on the Net Asset Value of the Fund; (ii) the Directors may temporarily suspend the calculation of the Net Asset Value and any subscription, repurchase and exchange of Shares and payment of repurchase proceeds in accordance with the provisions of the Prospectus under the section "Suspension of Calculation of Net Asset Value"; and/or (iii) the Directors may, in certain circumstances</p>	<p><b>INVESTMENT RISKS</b></p> <p>Investment in the Fund carries with it a degree of risk including the risks described in the "<i>Risk Information</i>" section of the Prospectus and in this Supplement. These risks are not intended to be exhaustive and potential investors should review the Prospectus and this Supplement carefully and consult with their professional advisers before purchasing Shares.</p> <p>In the event that the Fund uses FDI, the risk profile of the Fund may increase. For information in relation to the risks associated with the use of FDI, please note the following specific risks listed below. Please also refer to "<i>Derivatives Risk</i>" in the "<i>Risk Information</i>" section of the Prospectus.</p> <p><b>Concentration Risk</b></p> <p>The Fund may invest a relatively large percentage of its assets in issuers located in a single country, a small number of countries, or a particular geographic region. In these cases, the Fund's performance will be closely tied to the market, currency, economic, political, or regulatory conditions and developments in that country or region or those countries and could be more volatile than the performance of more geographically-diversified funds.</p> <p>In addition, the Fund may concentrate its investments in companies in a particular industry, market or economic sector. When the Fund concentrates its investments in a particular industry, market or economic sector, financial, economic, business, and other developments affecting issuers in that industry, market or sector will have a greater effect on the Fund than if it had not concentrated its assets in that industry, market or sector.</p> <p>Further, investors may buy or sell substantial amounts of the Shares in response to factors affecting or expected to affect a particular country, industry, market or sector in which the Fund concentrates its investments, resulting in abnormal inflows or outflows of cash into or out of the Fund. These abnormal inflows or outflows may cause the Fund's cash position or cash requirements to exceed normal levels, and consequently, adversely affect the management of the Fund and the Fund's performance.</p> <p><b>Currency Risk</b></p> <p>The Fund may invest in securities that are denominated in currencies that differ from the Base Currency. Changes in the values of those currencies relative to the Base Currency may have a positive or negative effect on the values of the Fund's investments denominated in those currencies. The Fund may, but will not necessarily, invest in currency exchange contracts to help reduce exposure to different currencies, however there is no guarantee that these contracts will successfully do so. Also, these</p>
-------------------------	--	---

	<p>as set out in the Prospectus, terminate the Fund.</p> <p>The value of investments and the income from them, and therefore the value of and income from the Shares can go down as well as up and an investor may not get back the amount invested. The Fund's exposure is linked to the performance of the components of the Reference Index which, in turn, is exposed to general market movements (negative as well as positive).</p>	<p>contracts may reduce or eliminate some or all of the benefit that a Fund may experience from favourable currency fluctuations.</p> <p><b>Index Risk</b></p> <p>The ability of the Fund to achieve significant correlation between the performance of the Fund and the Index may be affected by changes in securities markets, changes in the composition of the Index, cash flows into and out of the Fund and the fees and expenses of the Fund. The Fund will seek to track Index returns regardless of the current or projected performance of the Index or of securities comprising the Index. As a result, the Fund's performance may be less favourable than that of a portfolio managed using an active investment strategy. The structure and composition of the Index will affect the performance, volatility and risk of the Index (in absolute terms and by comparison with other indices), and consequently, the performance, volatility and risk of the Fund.</p> <p><b>Index Tracking Risk</b></p> <p>There is no guarantee that the investment objective of the Fund will be achieved. In particular, no financial instrument enables the returns of the Index to be reproduced or tracked exactly. Changes in the investments of the Fund and re-weightings of the relevant Index may give rise to various transaction costs (including in relation to the settlement of foreign currency transactions), operating expenses or inefficiencies which may adversely impact the Fund's tracking of the performance of an Index. Furthermore, the total return on investment in the Shares will be reduced by certain costs and expenses which are not taken into account in the calculation of the applicable Index. Moreover, in the event of the temporary suspension or interruption of trading in the investments comprising the Index, or of market disruptions, rebalancing the Fund's investment portfolio may not be possible and may result in deviations from the return of the Index.</p> <p><b>Investment Risk</b></p> <p>A Shareholder may lose the entire principal amount invested in the Fund. The value of the securities held in the Fund may increase or decrease, at times rapidly and unexpectedly. An investment in the Fund may at any point in the future be worth less than the original amount invested.</p> <p>The total return on investment in the Shares may be reduced by taxes arising in the Fund including taxes in the jurisdictions in which the Fund invests. The Fund may benefit from reduced dividend withholding taxes under the terms of relevant double taxation treaties or conventions although there is no guarantee that it will do so. Please refer to the "Tax Information" section of the Prospectus for further information on the applicable tax treatment for the Company and the Fund.</p>
--	---	--

<p><b>Business Day</b></p>	<p>any day (other than a Saturday or Sunday) on which (i); the Trans-European Automated Real-time Gross Settlement Express Transfer (TARGET) system is open; (ii) the markets on which 75% of the components of the Reference Index are traded are open; (iii) the Reference Index is calculated by the Index Provider; (iv) the clearing agent is open for business; and (v) foreign exchange markets are open and settle payments (including dealings in foreign exchange and foreign currency deposits), or such other day or days as the Directors may from time to time determine and notify in advance to Shareholders. For the avoidance of doubt, all non-Business Days will be published on the Website and there shall be at least one Dealing Day per fortnight.</p>	<p>Each normal bank business day in Ireland, inclusive of all public and/or bank holidays other than the following – New Year’s Day, Good Friday, Easter Monday, Christmas Day and St. Stephen’s Day – and days on which the Primary Stock Exchange, on which the constituents of the Index are traded, is open for trading, except individual, non-statutory rest days and days on which the Primary Stock Exchange in the main countries in which the Fund invests are closed, or on which 50% or more of the investments of the Fund cannot be adequately valued and/or such other day or days as the Directors and/or the Manager may determine and notify in advance to Shareholders.</p>
<p><b>Dealing Day</b></p>	<p>any Business Day (other than 2 January, Good Friday, Easter Monday, 1 May, Ascension Day, Whit Monday, 24 December, 26 December and 31 December) or such other days as the Directors may determine and notify to Shareholders in advance.</p>	<p>Every Business Day (excluding (i) any day on which a market on which securities included in the Index are listed or traded is closed and (ii) any day where the Index is not calculated) and/or such other day or days as the Directors and/or the Manager may determine and notify to the Administrator and to Shareholders in advance, provided there shall be at least two Dealing Days at regular intervals in each month. A list of such closed market days will be published for the Fund in advance on the Website.</p>



<b>Dealing Deadline</b>	4:00 p.m. (Dublin time) one Business Day prior to the relevant Dealing Day, or such other time for the relevant Dealing Day as may be determined by Directors (or their duly appointed delegates) and notified in advance to Shareholders provided always that the Dealing Deadline is no later than the Valuation Point;	For subscriptions: 4.30 pm (Dublin time) on the relevant Dealing Day.  For redemptions: 4.30 pm (Dublin time) on the relevant Dealing Day.
-----------------------------	---	--

**Share Class Transfer Table**

Name of Fund	CSIF (IE) MSCI USA Blue UCITS ETF	UBS (Irl) ETF plc – MSCI USA NSL UCITS ETF
<b>Classes of Shares / Class Currencies</b>	Class B USD (ISIN: IE00BJBYDR19)	Class (USD) A-acc (ISIN: IE000OULL4R4)
	Class A USD (ISIN: N/A)	Class (USD) A-dis (ISIN: IE000R904VR3)
	Class AH EUR (ISIN: N/A)	Class (hedged to EUR) A-dis (ISIN: IE0006TR6GM1)
	Class BH EUR (ISIN: N/A)	Class (hedged to EUR) A-acc (ISIN: IE000F9T8ED7)
	Class AH CHF (ISIN: N/A)	Class (hedged to CHF) A-dis (ISIN: IE000UYX29M4)
	Class BH CHF (ISIN: N/A)	Class (hedged to CHF) A-acc (ISIN: IE000OIUW54)
<b>Total Expense Ratio</b>	Up to 0.15% per annum in respect of the Unhedged Share Classes Up to 0.18% per annum in respect of the Hedged Share Classes	Up to 0.09% per annum in respect of unhedged share classes Up to 0.12% per annum in respect of hedged share classes.
<b>Subscription Charge</b>	Up to 5%	N/A
<b>Repurchase Charge</b>	Up to 3%	N/A
<b>Exchange Charge</b>	Up to 3%	N/A
<b>Primary Market Transaction Charge</b>	Up to 1%	N/A

**Further Information**

The key features of the Fund and the Receiving Fund are set out in the table above, in order to bring changes where relevant to the attention of investors.

This is intended as a brief summary of details of the Fund and the Receiving Fund.

In order to provide a more complete summary of the Receiving Fund, a copy of the Receiving Fund's PRIIPs KID is enclosed for your information at Schedule 3.

If you would like any further information about the Receiving Fund, please contact your usual contacts at the ICAV or the Receiving Platform.

**Schedule 2**  
**Timetable for the Proposals**

<b>Key dates</b>	
<b>Event</b>	<b>Date</b>
Documentation posted to the Shareholders	19 July 2024
Latest time and date for receipt of forms of proxy	14 August 2024
Meeting of Shareholders in the Fund	16 August 2024 (the " <b>EGM</b> ")
Results of EGM posted on <a href="https://am.credit-suisse.com/notice-to-investors">https://am.credit-suisse.com/notice-to-investors</a>	16 August 2024
<b>Subject to the resolution to be tabled at the EGM being passed:</b>	
Redemption Deadline	20 August 2024  This is the last Dealing Day, if the Merger receives regulatory and Shareholder approval, as of which shares of the Fund may be redeemed before the Merger takes effect
The final NAV for the Fund	Close of business on 23 August 2024 (the " <b>Valuation Point</b> ").  Shareholders should note that any income, dividends and other receivables accrued as of the Valuation Point will be included in the calculation of the final Net Asset Value of the Fund and will be transferred to the Receiving Fund as part of the Merger.  The Merger becomes binding on any shareholder of the Fund who has not redeemed or switched out of the Fund by this date.
Suspension Period	21 August 2024 - 23 August 2024  All dealing in the shares of the Fund shall be suspended during this period pending the Merger taking effect.
Valuation of the Fund and calculation of the exchange ratio	23 August 2024
Effective Time	00:00:01 a.m. (Irish time) on 26 August 2024  New Shares in the Receiving Fund are issued to the Fund Shareholders and their shares in the Fund are cancelled.
First day of dealing in New Shares issued in the Receiving Fund pursuant to the Merger	26 August 2024

Written confirmation posted to Shareholders advising of allocation and number of New Shares in the Receiving Fund

Within five (5) business days of the Effective Time.

**Schedule 3**  
**Key Information Document for the Receiving Fund**

# Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

## CSIF (IE) MSCI USA Blue UCITS ETF (the "Fund") A sub-fund of Credit Suisse Index Fund (IE) ETF ICAV (the "ICAV")

Class B USD Shares, ISIN: IE00BJBYDR19

The Fund is managed by Carne Global Fund Managers (Ireland) Limited (the "Manager")

### Objectives and Investment Policy

#### Investment Objective

The Fund's investment objective is to track the return of the MSCI USA Index (the "Reference Index") minus the fees and expenses of the Fund.

#### Investment Policy

The Fund is passively managed aiming to replicate the performance of the Reference Index. The Reference Index is a free float-adjusted, market capitalisation weighted index designed to measure equity market performance in the US pursuant to the rules applicable to the Reference Index. The portfolio and the performance of the Fund can deviate from the Reference Index. Under normal market conditions, it is expected that the anticipated level of tracking error will be less than 0.60%.

To achieve its objective, the Fund seeks to invest all or substantially all of its net proceeds of shares issued in a representative selection of US equities and equity-related securities which relate to the components of the Reference Index. Investment selection is not guided by growth or value but rather the investment objective of the Fund of tracking the return of the Reference Index.

The Fund may also temporarily invest in Equities and Equity-Related Securities and rights of companies which are not contained in the Reference Index. The maximum investment is 5% of the Net Asset Value ("NAV").

The Fund may also engage in Financial Derivative Instruments ("FDIs") for the purposes of efficient portfolio management and/or to protect against exchange risks. Such FDI's include warrants, FX forwards, futures on the Reference Index, futures on financial indices. Global exposure and leverage of FDI's shall not exceed 100% of the NAV.

In addition to the securities mentioned above, the Fund may invest in units of a passively managed collective investment schemes, both domestic and foreign and listed and unlisted, that are consistent with the investment objective and

meet with the requirements of the UCITS Regulations. The Fund shall not invest more than 10% of its NAV in other UCITS or other collective investment schemes. Investments which are dropped from the Reference Index must be sold within an appropriate period while safeguarding the interest of the investors.

The Fund's base currency is USD.

#### Distribution Policy

For non-distributing share classes, income will be automatically reinvested in the Fund and reflected in the NAV per share. For distributing share classes, income will be paid in the form of a dividend.

#### Dealing Frequency


You can buy and redeem units daily, on any business day (as defined in the supplement) other than on 2 January, Good Friday, Easter Monday, 1 May, Ascension Day, Whit Monday, 24 December, 26 December and 31 December or such other days as the Directors may determine and notify to shareholders in advance.

#### Recommendation

The Fund is suitable for investors with high risk tolerance and a long-term view who wish to invest in a broadly diversified portfolio of US equity securities. You should carefully consider your own investment goals and risk tolerance before investing in the Fund.

For more information about the investment policy and strategy of the Fund, please refer to the section entitled "Investment Objective, Investment Policies and Investment Strategy" of the Fund's Supplement (the "Supplement").

### Risk and Reward Profile



This indicator above is based on historical data and may not be a reliable indication of the future risk profile of the Fund. The risk category shown is not guaranteed and may change over time. The lowest category does not mean a risk-free investment.

This Fund is in risk category 6 due to the underlying performance of historical data returns.

The Fund may be subject to risks which are not included in the calculation of the risk- reward indicator. Key risk factors:

**Market Risk:** The risk that the market will go down in value, with the possibility that such changes will be sharp and unpredictable.

**Currency Risk:** The Fund's investments may be denominated in currencies other than the currency of the share class purchased by the investor which may be affected by adverse currency movements. In hedged share classes, the Fund will attempt to use FDIs to remove the effect of such currency movements, however there is no guarantee that any attempts at hedging will be successful.

**Derivative Risk:** The Fund may invest in FDI's to protect against risk for the purpose of efficient portfolio management. There is no guarantee that the Fund's use of FDIs for either purpose will be successful. Derivatives are subject to counterparty risk (including potential loss of instruments) and transactions are highly sensitive to underlying price movements, interest rates and market volatility and therefore come with a greater risk than directly investing in the underlying securities themselves.

**Operational Risk (including safekeeping of assets):** The Fund and its assets may experience material losses as a result of technology/system failures, cybersecurity breaches, human error, policy breaches and/or incorrect valuation of units.

**Liquidity Risk:** The Fund may invest in securities which may become difficult to sell or may need to be sold at an unfavourable price. This may affect the overall value of the Fund.

**Political and Legal Risks:** Investments are exposed to changes of rules and standards applied by a specific country. This includes restrictions on currency convertibility, the imposing of taxes or controls on transactions, the limitations of property rights or other legal risks.

Attention is drawn to the risk that the value of the principal invested in the Fund may fluctuate.

**For more information on risks, please see the section entitled "Risk Factors" in the Prospectus of the ICAV and the Supplement.**

## Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

### One-off charges taken before or after you invest:

Entry Charge	None
Exit Charge	None

This is the maximum amount that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.

### Charges taken from the Fund over a year:

Ongoing Charges	0.09%
-----------------	-------

### Charges taken from the Fund under certain specific conditions:


Performance Fee	Class B USD Shares	None
-----------------	--------------------	------

The Fund does not apply entry or exit charges.

The ongoing charges figure shown here is based on the total expense ratio of the Fund that the investment manager has agreed to cap (the "TER Cap"). The Investment Manager gives a commitment to respect the published figure shown. The Fund's annual report for each financial year will include details on the exact charges made. The ongoing charge figure may vary from year to year and excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another collective investment undertaking.

More detailed information about the charges can be found in the "Fees and Expenses" section of the Supplement.

## Past performance



The Fund was established in 2020.

**Past performance is not a guarantee of future performance.** In general, past performance takes into account all of ongoing charges, but not any entry, exit or switching charge. Past performance shall be calculated in USD. **The value of your investment may go down as well as up and you may not get back the amount you originally invested.**

## Practical Information

**Depository Bank:** The Fund's assets are held with the depository, Brown Brothers Harriman Trustee Services (Ireland) Limited.

**Further Information:** Further information about the ICAV, copies of the Prospectus, latest annual and semi-annual reports may be obtained free of charge from [www.credit-suisse.com](http://www.credit-suisse.com) and at the registered office of the ICAV.

**Representative Share Class Information:** This KIID for Class B USD Shares has been chosen as the representative share class for Class A USD Shares, Class A EUR Shares, Class B EUR Shares, Class AH EUR Shares, Class BH EUR Shares (ISIN: IE00BKKFSZ52), Class AH CHF Shares and Class BH CHF Shares (ISIN: IE00BKKFSY46). Further information on these classes is available in the sub-fund supplement.

**Latest Share Prices/Net Asset Value:** The latest share prices will be made available on [www.credit-suisse.com](http://www.credit-suisse.com) (or by contacting the Administrator, Brown Brothers Harriman Fund Administration Services (Ireland) Limited).

**Remuneration Policy:** Details of the remuneration policy of the Fund are available on the Manager's website, [www.carnegroup.com/resources](http://www.carnegroup.com/resources). A paper copy will be available free of charge from the office of the Manager upon request.

**Conversion of Shares:** A Shareholder may switch from one share class or one sub-fund to another share class or sub-fund subject to the conditions set out in the Prospectus, no exchange charge will be applied. Please refer to the Prospectus and the Supplement for the Fund for further details on how to exercise your right switch.

**Tax Legislation:** The taxation of income and capital gains of the ICAV and of the Shareholders is subject to the fiscal laws and practices of Ireland, of the countries in which the ICAV invests and of the jurisdictions in which the Shareholders are resident for tax purposes or otherwise subject to tax. Depending on your country of residence, this may impact your personal tax position. For further details, please speak to your financial adviser.

**Accuracy Statement:** The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Prospectus.

**Segregated Liability:** The Fund is a sub-fund of the ICAV, a company with an umbrella structure. Under Irish law the assets and liabilities of the Fund are segregated from other sub-funds within the ICAV and the assets of the Fund will not be available to satisfy the liabilities of another fund of the ICAV.

This Fund is authorised in Ireland and regulated by Central Bank of Ireland. The Manager is authorised in Ireland and regulated by the Central Bank of Ireland.



# Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

**UBS (Irl) ETF plc - MSCI USA NSL UCITS ETF (the "Fund"), a sub-fund of UBS (Irl) ETF plc (the "Company"), class (USD) A-acc (ISIN: IE000OULL4R4)**

This Fund's management company is UBS Fund Management (Ireland) Limited, a subsidiary of UBS AG.

## Objectives and investment policy

The Fund is passively managed and seeks to track performance of the The MSCI USA Index (Net Return) (the 'Index'). The Fund will seek to hold all of the shares of the Index, in the same proportions as the Index, so that essentially the portfolio of the Fund will be a near mirror image of the Index. In seeking to implement its investment objective of tracking the performance of the Index, the Fund may also in exceptional circumstances hold securities which are not comprised in its Index, including, for example, securities in respect of which there has been an announcement or it is expected that they will shortly be included in the Index. The Fund may, for the purpose of reducing risk, reducing costs or generating additional capital or income, use derivative instruments. The use of derivative instruments may multiply the gains or losses made by the Fund on given investment or on its investments generally.

Currency hedged share classes may also be available in the Fund. This sub-fund promotes environmental and/or social characteristics but does not have a sustainable investment objective. The Fund will not enter into any securities lending.

Investors other than authorized participants may not subscribe for shares directly with UBS (Irl) ETF plc, but may purchase and sell shares, through an intermediary, on one of the stock exchanges listed for the share class on the website [www.ubs.com/etf](http://www.ubs.com/etf). In exceptional circumstances, direct redemptions with UBS (Irl) ETF plc, are however possible on each dealing day (as set out in the relevant supplement to the prospectus). Authorized participants may subscribe and redeem shares with the UBS (Irl) ETF plc under the conditions detailed in the relevant authorized participant agreement.

Fund income is not paid out, but instead will be reinvested.

## Risk and reward profile



### Further material risks

- The Fund may use derivatives which can reduce investor risks or give rise to market risks as well as potential loss due to failure of counterparty.
- Every fund reveals specific risks, a detailed and comprehensive list of risk descriptions can be found in the prospectus.

### More about the risk category

- The risk category is based on the estimated future volatility of the Fund. The method used for this estimate depends on the fund type and historical data.
- Historical performance is not a reliable indicator for future performance.
- The risk category allocated is not static and may vary over time.
- Allocation to the lowest risk category does not mean that an investment in this fund is free of risk.

### Why is this Fund in this Category?

The Fund is in risk category 6 because the volatility of its returns is very high.

## Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

### One-off charges taken before or after you invest<sup>1</sup>

Entry charge	0.00% <sup>2</sup>
Exit charge	0.00% <sup>2</sup>

### Charges taken from the fund over a year

Ongoing charges	0.09%
-----------------	-------

### Charges taken from the fund under certain specific conditions

Performance fee	none
-----------------	------

<sup>1</sup> This is the maximum that might be taken out of your money before it is invested / before the proceeds of your investment are paid out.


<sup>2</sup> Investors who deal on secondary markets will pay fees as charged by their stock brokers. These fees are publicly available on exchanges on which the shares are listed and traded and may also be obtained from the relevant stock brokers. Transaction costs related to dealing directly with the Fund will be payable by authorised participants.

The **ongoing charges** are estimated in the absence of historical data or when the calculated figure is considered unsuitable because of a material change. As soon as available or suitable, the calculated ongoing charges are reported and may differ from the estimate. They generally exclude:

- Portfolio transaction costs, except in the case of an entry/ exit charge paid by the Fund when buying or selling units in another collective investment undertaking

For more information, please see the charges section of the Fund's prospectus, which is available at [www.ubs.com/etf](http://www.ubs.com/etf).

## Past performance



The class was launched in 2024.

## Practical information

### Depository

State Street Custodial Services (Ireland) Limited

### Further Information

UBS (Irl) ETF plc (the "Company") is established as a segregated portfolio company and can have multiple sub-funds. As a matter of Irish law, the assets of the Fund will not be available to satisfy the liabilities of another sub-fund of the Company. Information about the Fund and available share classes, the Company's full prospectus as well as the latest annual and semi-annual reports, can be obtained free of charge, in English on request in writing from the Administrator at 78 Sir John Rogerson's Quay, Dublin 2, Ireland. Details of the remuneration policy of the management company relating to how remuneration and benefits are calculated, the people responsible for awarding the remuneration and benefits and the composition of the remuneration committee (where such a committee exists) are available on [www.ubs.com/manco-fmie](http://www.ubs.com/manco-fmie). A paper copy of the full policy is available free of charge upon request.

The currency of the share class is USD.

The latest Net Asset Value, details of the Fund's portfolio and indicative intra-day Net Asset Value of the Fund is available at [www.ubs.com/etf](http://www.ubs.com/etf).

### Tax Legislation

The Company is subject to the tax laws and regulations of Ireland. Depending on your own country of residence, this might have an impact on your investment. For further details you should consult a tax adviser.

### Liability Statement

UBS Fund Management (Ireland) Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus of the Fund.

**Schedule 4**  
**Notice of Extraordinary General Meeting**

**Credit Suisse Index Fund (IE) ETF ICAV (the "ICAV")**  
**CSIF (IE) MSCI USA Blue UCITS ETF (the "Fund")**

**NOTICE** is hereby given that an Extraordinary General Meeting of the Shareholders of the Fund, held via electronic communications technology, namely Microsoft Teams, originating from 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland on 16 August 2024 at 10.00 a.m. (Irish time) for the purpose of considering and if thought fit, passing the following resolution as a special resolution of the Fund:

1. That the proposed merger of the Fund into the Receiving Fund on the terms and conditions as set out in the enclosed Shareholder circular, be and are hereby approved.

Dated this 19 July 2024.

*By Order of the Board*

---

**Secretary**

Note: As a result of the ICAV's use of the ICSD settlement model, The Bank of New York (Depository) Nominees Limited is the only registered shareholder of the ICAV. The Bank of New York (Depository) Nominees Limited being the only registered shareholder of the Fund, is entitled to appoint a proxy or an authorised representative to attend, speak and vote on its behalf. A proxy or an authorised representative need not be a member of the Fund. The form of proxy enclosed with this notice of EGM is therefore only for use by the sole registered shareholder of the Fund and not by any investors who have purchased their shares on the secondary market. To be valid, this form, including the original or notarially certified copy of such power or authority must be completed and returned via email to [carnecosec@carnegroup.com](mailto:carnecosec@carnegroup.com) with the original to follow by post to Credit Suisse Index Fund (IE) ETF ICAV, 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland, not less than 48 hours before the time fixed for holding the EGM or any reconvened EGM.

**Schedule 5  
Form Of Proxy**

**Credit Suisse Index Fund (IE) ETF ICAV (the "ICAV")  
CSIF (IE) MSCI USA Blue UCITS ETF (the "Fund")**

I/We \_\_\_\_\_  
being a Shareholder(s) of the above named Fund, hereby appoint the chairperson of the ICAV or failing them \_\_\_\_\_ or failing that, any representative of Carne Global Fund Managers (Ireland) Limited, 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland or failing them as my/our\* proxy to vote for me/us\* on my/our\* behalf at the Extraordinary General Meeting of the Fund to be held via electronic communications technology, namely Microsoft Teams, originating from 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland on 16 August 2024 at 10.00 a.m. (Irish time) or at any reconvened meeting thereof.

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

Please indicate with an "X" in the spaces below how you wish your vote to be cast for the resolution.

<b>Special Resolution</b>	<b>For</b>	<b>Against</b>
"That the proposed merger of the Fund into the Receiving Fund on the terms and conditions as set out in the enclosed Shareholder circular, be and hereby is approved."	<input type="checkbox"/>	<input type="checkbox"/>
Unless otherwise instructed above the Proxy shall vote as they see fit.		

**Credit Suisse Index Fund (IE) ETF ICAV (the "ICAV")**  
**CSIF (IE) MSCI USA Blue UCITS ETF (the "Fund")**

**Notes**

1. If you have sold or otherwise transferred all of your Shares, please pass this Circular and accompanying Form of Proxy as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for delivery to the purchaser or the transferee.
2. As a result of the ICAV's use of the ICSD settlement model, The Bank of New York (Depository) Nominees Limited is the only registered shareholder of the ICAV.
3. The Bank of New York (Depository) Nominees Limited being the only registered shareholder of the Fund, is entitled to appoint a proxy or an authorised representative to attend, speak and vote on its behalf. A proxy or an authorised representative need not be a member of the Fund. The form of proxy enclosed with this notice of EGM is therefore only for use by the sole registered shareholder of the Fund and not by any investors who have purchased their shares on the secondary market.
4. Investors in the Fund should submit their voting instructions through an ICSD or through a participant in the ICSD being their local central securities depository (which in turn should be instructed to submit their voting instructions to the ICSD) to ensure the sole registered shareholder of the Fund votes in accordance with their instructions. Investors who have invested in the Fund via their brokers, dealers or intermediaries should contact these entities to provide voting instructions to the ICSD on their behalf. In accordance with their respective rules and procedures, each ICSD is required to collate and transfer all votes received from its participants to the ICAV's common depository, The Bank of New York Mellon, London Branch (the "**Common Depository**"), and the Common Depository is, in turn, required to collate and transfer all votes received from each ICSD to The Bank of New York (Depository) Nominees Limited, which is obligated to vote in accordance with the Common Depository's voting instructions. Investors should consult with their brokers, dealers or intermediaries to understand any timing implications for them in this regard.
5. If you do not insert a proxy of your own choice it shall be assumed that you wish to appoint the Chair of the meeting or one of the other persons mentioned above to act for you.
6. Proxies for the meeting are also valid for any reconvened EGM.
7. If the instrument appointing a proxy is signed under a power of attorney, please ensure that you enclose an original or a notarially certified copy of such power of attorney with your Form of Proxy.
8. If this form is returned without any indication as to how the person appointed proxy shall vote they will exercise their discretion as to how they vote or whether or not they abstain from voting.
9. Any alterations made to this form must be initialled to be valid.
10. To be valid, this form, including the original or notarially certified copy of such power or authority must be completed and returned via email to [carnecosec@carnegroup.com](mailto:carnecosec@carnegroup.com) with the original to follow by post to Credit Suisse Index Fund (IE) ETF ICAV, 3rd Floor, 55 Charlemont Place, Dublin, D02 F985, Ireland, not less than 48 hours before the time fixed for holding the EGM or any reconvened EGM.